Stay updated on Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.

Latest updates to the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe study record shows recruitment has closed to new participants and the record has been revised to version v3.6.0, replacing the prior v3.5.5 label.SummaryDifference0.4%

- Check9 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the study history page.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe bottom revision stamp updates from v3.5.3 to v3.5.4, reflecting a new revision of the record history. This indicates the study record has been updated.SummaryDifference0.1%

- Check52 days agoChange DetectedUpdated the ClinicalTrials.gov interface/revision label from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 in the history.SummaryDifference0.1%

Stay in the know with updates to Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.